Metopirone Test Research Articles

Application of the metopirone test to tumors in the region of the sella turcica.

Application of the metopirone test to tumors in the region of the sella turcica.

THE DIENCEPHALIC SYNDROME OF EARLY INFANCY DUE TO SILENT BRAIN TUMOR: WITH SPECIAL REFERENCE TO TREATMENT

Three patients with typical "diencephalic syndrome" have been described. The clinical observation of an emaciated and pale, but remarkably bright, cheerful, and active infant with a normal or increased appetite and food intake should suggest the diagnosis. Physical findings are conspicuous by their absence, although mild nystagmus, tremor, or ataxia may occasionally be present. An elevated total eosinophil count and an elevated cerebrospinal fluid protein are important, though not invariable, features. Metopirone test coupled with ACTH-adrenal stimulation test indicate markedly reduced pituitary reserve. Diagnosis is confirmed by pneumoencephalography and biopsy. It is likely that with increasing knowledge, the clinical spectrum of this syndrome will be broadened, and one might expect to find, on occasions, anorexia rather than increased appetite, lassitude rather than hyperactivity, irritability rather than euphoria, obesity rather than emaciation, and different combinations of all of these features. The results of therapy with beam-directed cobalt irradiation are encouraging.

Metopirone test in overweight subjects.

ABSTRACT The metopirone test was performed in 54 subjects: 49 overweight subjects and 5 controls. While normal in some of these, the test showed a poor reaction in a group of 14 overweight children, 12 of them being boys with a gynoid type of obesity. It is suggested that the poor reaction to metopirone possibly represents only one aspect of reduced pituitary functional state – including gonadotrophins – and, if confirmed, these findings may support the concept of a functional Babinski-Fröhlich syndrome.

Corticotrophin secretion in patients with head injuries examined by the metopirone test.

Corticotrophin secretion in patients with head injuries examined by the metopirone test.

CLINICAL ASSESSMENT OF THE PERORAL METOPIRONE TEST.

Acta Medica ScandinavicaVolume 178, Issue 1 p. 1-11 Clinical Assessment of the Peroral Metopirone Test Jørn Ditzel, Jørn Ditzel Medical Department C, (Head: P. From Hansen, M. D.), Copenhagen County Hospital in Glostrup, and Medical Department B (Head: P. Riis, M. D.), Copenhagen County Hospital in Gentofte, DenmarkSearch for more papers by this author Jørn Ditzel, Jørn Ditzel Medical Department C, (Head: P. From Hansen, M. D.), Copenhagen County Hospital in Glostrup, and Medical Department B (Head: P. Riis, M. D.), Copenhagen County Hospital in Gentofte, DenmarkSearch for more papers by this author First published: January/December 1965 https://doi.org/10.1111/j.0954-6820.1965.tb04245.xCitations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume178, Issue1January/December 1965Pages 1-11 RelatedInformation

前立腺癌の内分泌学的研究

(1) Both ACTH and Metopirone tests were performed on twelve patients with prostatic carcinoma before and after several kinds of endocrinologic treatments, in order to investigate the changes in pituitary-adrenal functions. Urinary 17-OHCS (Porter-Silber chromogens) was measured in succession before and after ACTH and Metropirone administrations. The treatments consisted of castration, estrogen administration and pituitary irradiation.(2) Pre-treatment levels of urinary 17-OHCS in the patients of postatic carcinoma did not differ from those of controls of same age. And there was no abnormality in the results of ACTH and Metpirone test before any treatments.(3) Ten to twelve days after castration, urinary 17-OHCS levels showed a slight, but insignificant elevation. The results of ACTH and Metopirone tests showed no significant difference from the pre-treatment values.(4) Estrogen administration resulted in reduction of urinary 17-OHCS, which was restored to the pre-treatment levels as soon as estrogens were withdrawn. A marked reduction in pituitary ACTH reserve was observed during estrogen administration, while the results of ACTH tests did not show any changes. Though the changes of Metopirone tests were marked during estrogen therapy, they returned soon to the pre-treatment values with the withdrawal of estrogen, even if after administration of a longer period.(5) After pituitary irradiation of 4, 000 to 7, 500r (surface doses) the urinary 17-OHCS levels remained within the control values. The results of ACTH and Metpirone tests showed on abnormality following irradiation of 4, 000 to 6, 000r, but a patient who had received 7, 500r irradiation showed a moderate reduction of pituitary ACTH reserve.(6) Reduction in pituitary ACTH reserve during estrogen administration indicated the possibility that estrogen administration might suppress the pituitary function as inhibiting ACTH secretion in some degree, because the results of ACTH tests showed no changes. It is suggested that the effectiveness of estrogens on postatic carcinoma might be explained not only by antagonistic action against androgens and suppressive action of gonadotropin secretion, but also by suppression of adrenal androgen-secretion due to ACTH inhibition. Estrogen administration should be continued as long as hormone dependency of the carcinoma was maintained. It was also verified that estrogen administration did not supperess adrenal function.(7) In cases of pituitary irradiation no replacement of corticoides was required provided that the doses remained within 6, 000r. In cases of irradiation more than 7, 500r, replacement therapy of corticosteroids should be instituted of Metopirone test, which was one of reasonable indicators of the pituitary functions, showed a reduction of pituitary ACTH reserve.

Falsely Abnormal Responses of Normal Subjects to the Metopirone (Su-4885) Test for Pituitary ACTH Reserve

Falsely Abnormal Responses of Normal Subjects to the Metopirone (Su-4885) Test for Pituitary ACTH Reserve

ASSESSMENT OF PITUITARY ACTH SECRETORY CAPACITY WITH METOPIRONE: II. COMPARISON WITH OTHER TESTS.

The Metopirone test has been compared to 2 other measures of pituitary ACTH secretion, the insulin tolerance test and the water-loading test, in a variety of patient groups. The results confirm the impression that the Metopirone test is the most sensitive measure now available for assessing pituitary ACTH secretory capacity. Discrepancies between the Metopirone and insulin tolerance tests were noted, indicating that the Metopirone test should be considered a measure of only one aspect of pituitary ACTH secretory capacity, and not necessarily a measure of total reserve.

ASSESSMENT OF PITUITARY ACTH SECRETORY CAPACITY WITH METOPIRONE: 1. INTERPRETATION.

Confusion exists as to the proper interpretation of the Metopirone test of pituitary ACTH secretory capacity. Criteria were examined using oral and intravenous tests in a variety of patient groups. The tests were interpreted by measuring changes in the urinary excretion of Porter-Silber chromogens and 11-deoxycorticosteroids (11-DOCS) and plasma levels of 11-DOCS. The changes in urinary 11-DOCS excretion were found to differentiate most clearly the normal and abnormal responses. The normal response as denned by this study is an increase in 11-DOCS excretion of at least 7 mg/day above the control level.

A New Method of Pituitary Exploration and Its Use with Children: The Metopirone Test

SummaryFrom these observations, it emerges that the Metopirone test is a valuable method of establishing, given an endocrine or metabolic syndrome, the existence of a hypophyseal insufficiency. This appears to us to be of particular interest in pediatrics for a diagnosis of cases of arrested development and dwarfism where a hypophyseal cause often appears possible, but not certain. A negative or diminished response to Metopirone establishes almost invariably the hypothalamo‐hypophyseal origin of retarded growth, though a normal response does not exclude this etiology, for the Metopirone test confirms and specifies the existence in the child of dissociated anterior hypophyseal insufficiencies.